關(guān)鍵詞

戈沙妥珠單抗 米托坦 帕金森病 酪氨酸激酶抑制劑 端粒酶抑制劑 塞普替尼 莫洛利單抗 依沃西單抗 帕博利珠單抗

?

#今日行業(yè)熱點#

①The Lancet：Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

臨床試驗：戈沙妥珠單抗（sacituzumab govitecan）用于激素受體陽性和人表皮生長因子受體2（HER2）陰性轉(zhuǎn)移性乳腺癌(TROPiCS-02)的總生存率:一項隨機、開放標簽、多中心、Ⅲ期試驗

②The Lancet Diabetes and Endocrinology：Human POT1 protects the telomeric ds-ss DNA junction by capping the 5′ end of the chromosome

臨床試驗：米托坦（Mitotane）輔助治療與監(jiān)測低級別局限性腎上腺皮質(zhì)癌(ADIUVO):一項國際、多中心、開放標簽、隨機、Ⅲ期試驗和觀察性研究

③The Lancet Neurology：Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

全基因組關(guān)聯(lián)研究：非洲和非洲混合人群中與帕金森病相關(guān)的遺傳風險位點和因果關(guān)系的識別

④The Lancet Haematology：Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures

通過對患者報告內(nèi)容有效性的系統(tǒng)回顧和評估測量慢性粒細胞白血病TKI（酪氨酸激酶抑制劑）相關(guān)的毒性作用

⑤The Lancet Infectious Diseases：Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial

臨床試驗：在布基納法索和馬里對5歲以下兒童接種帶有或不帶有季節(jié)性瘧疾化學預防的RTS,S/AS01E疫苗:一項雙盲、隨機、對照、Ⅲ期試驗

⑥The Lancet Respiratory Medicine：Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials

臨床分析：識別膿毒癥的分子表型:兩項前瞻性觀察隊列分析和兩項隨機對照試驗的二次分析

⑦全球首款端粒酶抑制劑GRN163L（Imetelstat）的新藥申請獲FDA受理，用于低危骨髓增生異常綜合征（LR-MDS）患者的輸血依賴性貧血

⑧RET抑制劑塞普替尼（selpercatinib）用于初治、RET突變型晚期或轉(zhuǎn)移性甲狀腺髓樣癌（MTC）的III期LIBRETTO-531研究達到主要終點

⑨靶向于CD47的單克隆抗體和LSC抑制劑莫洛利單抗Magrolimab用于急性髓系白血?。ˋML）的美國臨床研究已被FDA叫停

⑩PD-1/VEGF雙特異性抗體依沃西單抗國際多中心注冊性III期研究即將在中國啟動，評估依沃西單抗聯(lián)合化療對比帕博利珠單抗聯(lián)合化療用于轉(zhuǎn)移性鱗狀非小細胞肺癌（sq-NSCLC）的安全性和有效性

科學探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！